We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen offers Protein Degrader Animal Model Services, delivering comprehensive in vivo evaluation across multiple species and disease models, supporting translational validation, mechanism confirmation, and regulatory advancement for targeted protein degradation programs.
Protein degraders are small molecules with targeted degradation function against disease-causing proteins. For drug development, animal model testing is essential for optimization, safety assessment, and regulatory compliance. Laws worldwide currently require candidate drug testing in animals before human clinical trials. For half a century, the majority of drugs have been evaluated in mice, rats, dogs, monkeys, and other species, informing patient dosing strategies and safety profiles. Profacgen offers diverse animal tests for protein degraders, from ADME and pharmacokinetics through toxicology and efficacy evaluation.
Overview
Animal models are indispensable for protein degrader development, providing insights unattainable from in vitro systems:
Translational evaluation: Animal models bridge the gap between cellular activity and human therapeutic potential by capturing systemic exposure, tissue distribution, metabolism, and physiological feedback. While animal results do not always translate directly to human efficacy, they identify critical liabilities and guide experimental design refinement
Mechanism validation: In vivo confirmation that target degradation, pathway modulation, and phenotypic responses are degrader-mediated, proteasome-dependent, and E3 ligase-specific. Mechanistic validation in intact organisms supports regulatory submissions and clinical trial design
Candidate selection: Multi-parameter comparison of lead compounds integrating exposure, target engagement, efficacy, and tolerability to identify development candidates with the highest probability of clinical success
Available Study Types
Profacgen provides comprehensive animal study capabilities spanning the full drug development spectrum:
Pharmacokinetic Studies
Characterization of absorption, distribution, metabolism, and excretion.
ADME evaluation: Plasma and tissue concentration-time profiles, bioavailability, clearance, volume of distribution, and half-life determination
Release process: Formulation-dependent absorption kinetics and sustained release characterization
Dosing interval optimization: PK modeling to predict optimal dosing frequency based on target half-life and recovery kinetics
Target Degradation Studies
Quantitative confirmation of in vivo target engagement and mechanism.
Tissue-level quantification: Western blot, ELISA, and mass spectrometry of target protein in tumor, organ, and blood samples
Time-course profiling: Degradation onset, maximal reduction, and recovery following single and repeat dosing
Mechanistic confirmation: Proteasome inhibitor co-administration and E3 ligase knockout validation
Pharmacodynamic Evaluation
Assessment of downstream pathway modulation and biomarker response.
Pathway biomarkers: Phosphorylation status, transcriptional changes, and proliferation markers correlating target loss with functional consequence
Circulating biomarkers: Plasma and serum analytes as surrogate endpoints for tissue-level target engagement
PK/PD modeling: Integration of exposure and response data to predict human efficacious dose and dosing regimen
Efficacy Studies
Therapeutic benefit assessment in disease-relevant models.
Tumor models: Growth inhibition, regression, and survival in xenograft, PDX, and syngeneic models
Inflammation models: Clinical score improvement, histopathology, and cytokine reduction in arthritis and colitis models
Neurological models: Behavioral endpoints, neuroimaging, and survival in neurodegeneration and CNS tumor models
Toxicity Assessment
Comprehensive safety evaluation to support regulatory advancement.
Acute toxicity: Single-dose tolerability and maximum tolerated dose determination
Repeated dose toxicity: Subchronic and chronic studies with clinical pathology, organ weights, and histopathology
Specialized toxicology: Developmental and reproductive toxicity, carcinogenicity, immunogenicity, anti-drug antibody, and neutralizing antibody assessment
Local tolerance: Stimulation tests in blood, vessels, muscles, eyes, and skin; hypersensitivity evaluation for active and passive allergy
Supported Disease Areas
Profacgen maintains established animal models across major therapeutic indications:
Oncology models: Subcutaneous and orthotopic xenografts, patient-derived xenografts (PDX), genetically engineered mouse models (GEMM), and syngeneic immunocompetent models. Models available for solid tumors, hematologic malignancies, and metastatic disease with luciferase imaging for longitudinal monitoring
Inflammation models: Collagen-induced arthritis, DSS-induced colitis, LPS challenge, and adjuvant-induced inflammation with clinical scoring, histopathology, and cytokine profiling endpoints
Neurological disease models: Orthotopic glioma, Alzheimer's disease transgenics (APP/PS1, 5xFAD), Parkinson's disease toxin models (MPTP, 6-OHDA), and multiple sclerosis models (EAE) with behavioral, neuroimaging, and neuropathological endpoints
Rare disease models: Custom-generated genetically modified models and commercially available strains for orphan indication evaluation, including lysosomal storage diseases, muscular dystrophies, and inherited metabolic disorders
Endpoints and Readouts
Profacgen quantifies diverse endpoints to comprehensively characterize degrader performance in vivo:
Target protein levels: Quantitative Western blot, ELISA, and mass spectrometry in tissue homogenates; immunohistochemistry for spatial distribution; and circulating exosome analysis for systemic target engagement
Biomarker changes: Downstream pathway readouts including phosphorylation, transcriptional markers, and metabolic indicators; circulating cytokines and chemokines for inflammation models; and neurodegeneration biomarkers (tau, Aβ, neurofilament) for CNS indications
Tumor growth inhibition: Caliper measurement, bioluminescence imaging, and MRI for longitudinal tumor monitoring; tumor growth delay, regression rate, and complete response assessment
Survival analysis: Kaplan-Meier curves with median survival, hazard ratios, and statistical significance; correlation with target degradation and biomarker response to establish exposure-response relationships
Multiple Animal Species and Wide Range of Assays: Mouse, rat, dog, and non-human primate models with established tumor, inflammation, neurological, and rare disease platforms; comprehensive PK, PD, efficacy, and toxicology capabilities.
Professional Team and Customized Services: Experienced veterinarians, study directors, and scientists with deep expertise in degrader pharmacology; tailored study design aligned to your specific program objectives and regulatory pathway.
Detailed Data and Reliable Analysis: Rigorous quality control, validated bioanalytical methods, robust statistical frameworks, and transparent data sharing ensure reproducible, decision-ready results.
Short Turnaround Time and Cost-Effective Pricing: Established model platforms, efficient workflows, and parallel processing deliver rapid, economical evaluation without compromising scientific rigor or regulatory compliance.
Representative Program Scenarios
Scenario 1: Integrated PK/PD/Efficacy in Xenograft Model
Program Context:
An oncology PROTAC required in vivo proof-of-concept integrating pharmacokinetics, target degradation, pathway modulation, and anti-tumor efficacy to support investor presentations and IND-enabling planning.
Objective:
To establish dose-exposure-response relationships, confirm tumor target degradation, and demonstrate tumor growth inhibition with mechanistic correlation.
Approach:
Profacgen established a subcutaneous xenograft model with weekly tumor monitoring. Mice were randomized to vehicle or three dose groups with PK sampling at multiple time points. Tumor target degradation was assessed by Western blot and IHC at 6 and 24 hours post-dose. Pathway biomarkers (phospho-ERK, Ki-67) were quantified by immunofluorescence. Tumor growth and survival were monitored for 6 weeks.
Outcome:
PK analysis revealed dose-proportional exposure with tumor concentrations 3-fold above plasma. Target degradation was dose-dependent, with >90% reduction at the highest dose. Pathway biomarkers correlated with target loss. Tumor growth inhibition was 35%, 62%, and 78% across dose groups, with the highest dose achieving tumor stasis. Survival was extended by 21 days. The integrated dataset supported IND submission and Phase 1 dose prediction.
Scenario 2: Toxicology Package for Regulatory Advancement
Program Context:
A lead molecular glue required a comprehensive toxicology package for IND submission, including acute toxicity, repeated dose tolerability, and local irritation assessment.
Objective:
To determine the maximum tolerated dose, identify target organs, assess reversibility, and evaluate local tolerance to support first-in-human trial design and starting dose selection.
Approach:
Profacgen conducted acute toxicity in rats with escalating doses to determine MTD. A 28-day repeated dose study was performed at three dose levels with clinical observations, body weights, clinical pathology, and full necropsy with organ weights and histopathology. Local tolerance was assessed by intravenous and intramuscular irritation scoring. Anti-drug antibody responses were monitored by ELISA.
Outcome:
Acute toxicity identified dose-limiting gastrointestinal effects at 100 mg/kg. The 28-day study established a no-observed-adverse-effect level (NOAEL) at 30 mg/kg with reversible liver enzyme elevations at higher doses. No local irritation or hypersensitivity was observed. The toxicology package supported IND filing and a predicted safe starting dose for Phase 1 of 3 mg.
Q: Which species are required for regulatory submission?
A: Regulatory agencies typically require one rodent and one non-rodent species for general toxicology. Mouse or rat serves as the rodent; dog or non-human primate as the non-rodent. Species selection depends on target and E3 ligase conservation, metabolic similarity, and historical precedent. We guide species selection based on your program and regulatory strategy.
Q: How do you ensure animal welfare and ethical compliance?
A: All studies are conducted under IACUC-approved protocols with veterinary oversight, humane endpoints, and refinement strategies minimizing pain and distress. We adhere to 3R principles (Replacement, Reduction, Refinement) and international guidelines including ARRIVE reporting standards.
Q: Can you use genetically modified models?
A: Yes. We maintain and can generate gene-engineered models, transgenic lines, and humanized mice expressing human target and E3 ligase. GEMMs are available for oncogene-driven tumors. Custom model development requires 3–6 months depending on complexity.
Q: What is the difference between xenograft and syngeneic models?
A: Xenografts use human tumor cells in immunocompromised mice, enabling evaluation of human-specific degraders but lacking immune context. Syngeneic models use mouse tumor cells in immunocompetent mice, preserving immune interactions but requiring cross-reactive degraders. Selection depends on mechanism and translational goals.
Q: How do you handle species differences in degrader metabolism?
A: We perform cross-species in vitro metabolism comparison using hepatocytes or microsomes from mouse, rat, dog, monkey, and human. Metabolite identification in vivo confirms predicted pathways. Allometric scaling and physiologically-based PK modeling bridge animal data to human predictions.
Q: What is the typical timeline for a full toxicology package?
A: Acute toxicity requires 2–4 weeks. A 28-day repeated dose study requires 8–12 weeks including in-life phase and histopathology. Developmental toxicity requires 4–6 months. A standard IND-enabling package (acute, 28-day, genotoxicity, local tolerance) typically delivers within 6–9 months.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
